Pharma Weakens FDA Oversight as the Price of Letting Congress Increase NIH Funding

Comment icon 0 Comments
Last Friday, July 10, the United States House of Representatives passed H.R. 6 by a vote of 344-77. Pennsylvania Congressmen Barletta, Boyle... Read more

Pharma's specialty drug pricing can torpedo US health care

Comment icon 0 Comments
This past February CVS/Caremark issued a report that forecast a new class of cholesterol drugs, the PCSK-9’s, will cost the U.S. health... Read more

Why pharma can't adapt to the changing health environment

Comment icon 0 Comments
In nearly every sector of health care, competing companies are acting aggressively to position themselves for prospering in a rapidly changing... Read more

Trans-Pacific Partnership: Pharma's payoff for Obamacare neutrality

Comment icon 0 Comments
In 1993 the new Clinton administration decided to make health care reform the signature issue of its first term. Bill Clinton appointed his... Read more

Health insurers balance long- and short-term moves but can pharma?

Comment icon 0 Comments
Commercial success for a new drug brand increasingly depends on whether and, how much, third-party payers will reimburse for it. As more physicians... Read more

One week, three lessons for pharma

Comment icon 0 Comments
The past week in pharma was one of those times when just setting the news items alongside one another in the proper order can tell someone... Read more

When a pharma spokesman advocates value-based pricing

Comment icon 0 Comments
The Forbes columnist and pharma cheerleader, John La Mattina, left Pfizer in 2008 as their R&D head with a $22.6 million package after... Read more

Less research training in medical school? That's actually good

Comment icon 0 Comments
In Sunday's Health section of the Inquirer, reporter Ilene Raymond Rush interviewed the dean of Temple's medical school, Arthur Feldman. The... Read more